Beam Therapeutics, which is developing a CRISPR-based technology, filed for its initial public offering, aiming to raise $100 million, Xconomy reported.
Other companies using CRISPR-Cas9 technology to develop new therapies include Caribou Biosciences, Editas Medicine, CRISPR Therapeutics and Intellia Therapeutics.
However, the ability to edit point mutations could make the Beam technology applicable to a broader range of genetic diseases, according to the new source.
Next year, Beam aims to show that it can base edit genes in animals, and said it could start filing for clearance to begin clinical testing for multiple programmes in 2021.
To read more NewsPoints articles, click here.